Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apellis Pharmaceuticals (APLS – Research Report), Dexcom (DXCM – Research Report) and Nanosonics Limited (NNCSF – Research Report).
Apellis Pharmaceuticals (APLS)
In a report issued on January 26, Derek Archila from Wells Fargo assigned a Hold rating to Apellis Pharmaceuticals, with a price target of $62.00. The company’s shares closed last Friday at $64.04.
According to TipRanks.com, Archila is a 4-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $73.69, which is an 11.6% upside from current levels. In a report issued on January 12, Wedbush also maintained a Hold rating on the stock with a $60.00 price target.
See the top stocks recommended by analysts >>
Dexcom (DXCM)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom on January 26 and set a price target of $145.00. The company’s shares closed last Friday at $121.96.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $143.36 average price target, implying a 13.7% upside from current levels. In a report issued on January 22, Canaccord Genuity also maintained a Buy rating on the stock with a $140.00 price target.
Nanosonics Limited (NNCSF)
Nanosonics Limited received a Hold rating and a A$3.95 price target from Wilsons analyst Shane Storey on January 24. The company’s shares closed last Wednesday at $1.97, close to its 52-week low of $1.96.
According to TipRanks.com, Storey is a 4-star analyst with an average return of
Currently, the analyst consensus on Nanosonics Limited is a Moderate Sell with an average price target of $2.50, representing a 27.6% upside. In a report issued on January 23, RBC Capital also maintained a Hold rating on the stock with a A$3.75 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APLS:
- Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
- Apellis announces negative CHMP opinion for pegcetacoplan for GA
- Apellis price target raised to $75 from $70 at Needham
- Apellis price target raised to $81 from $71 at Baird
- Apellis price target raised to $92 from $82 at H.C. Wainwright
